Drugs

VK2735

VK2735 is a dual GLP-1 and GIP receptor agonist developed by Viking Therapeutics for obesity, as an injection and in an oral form. The next event is Phase 3 start for Oral VK2735, expected Q4 2026 (source).

Also known as
oral VK2735
Company
How it works
Dual GLP-1 and GIP receptor agonist
Approved
Not approved in any market we track

Development by disease

ObesityPhase 3

Upcoming events

Estimated timing · a month, quarter, half-year or year-end the company gave

Past results and milestones

  • Oct 6, 2026
    Viking announced on October 6, 2026 that Part 2 of the VK2735 maintenance dosing study has been initiated in approximately 195 adults with obesity. Participants transition at Week 21 to oral daily or weekly, monthly subcutaneous, every-other-week subcutaneous, or placebo arms. Source
  • Sep 22, 2026
    Part 1 evaluated subcutaneous injections. Maintenance dosing study fully enrolled and readout completed. Induction phase (21 weeks weekly dosing) achieved 16–19% weight loss across VK2735 cohorts vs. 0% placebo. Maintenance phase (12 weeks) demonstrated up to 97% weight loss maintenance on every-other-week dosing and up to 90% on monthly dosing, with excellent tolerability and GI adverse event rates comparable to placebo. Source
  • Mar 26, 2026
    VANQUISH-2 Phase 3 trial enrollment completed with approximately 1,000 patients enrolled during Q1 2026. Source
  • Nov 19, 2025
    VANQUISH-1 Phase 3 RCT completed enrollment in November 2025 with >4,500 patients enrolled, exceeding original target and finishing ahead of schedule. Source
  • Aug 19, 2025
    VENTURE-Oral met its primary and secondary endpoints. Daily oral VK2735 produced dose-dependent mean weight loss of up to 12.2% after 13 weeks versus 1.3% with placebo, and most treatment-emergent adverse events were mild or moderate. Source
  • Jun 25, 2025
    Viking initiated the Phase 3 VANQUISH program: VANQUISH-1 in approximately 4,500 adults with obesity or overweight and a weight-related comorbidity, and VANQUISH-2 in approximately 1,100 adults with type 2 diabetes and obesity or overweight. Both trials evaluate weekly subcutaneous VK2735 over 78 weeks. Source
  • Feb 27, 2024
    The Phase 2 VENTURE trial of subcutaneous VK2735 in obesity met its primary and secondary endpoints, demonstrating statistically significant weight loss up to 14.7% after 13 weeks with 95% of GI adverse events mild/moderate. Source

Trials

Maintenance Dosing Study — Part 1Maintenance Dosing Study — Part 2VANQUISH-1VANQUISH-2VENTUREVENTURE-Oral
The investment thesis, what each upcoming event depends on and the competitive landscape are on the Viking Therapeutics page. Upcoming FDA decisions · All drugs